The following OncLive interview with leading renal cell carcinoma (RCC) expert, Dr Toni Choueiri from the Dana-Farber Cancer Institute in Boston, US, discusses the data from the JAVELIN-101 study comparing the avelumab/axitinib combination with sunitinib in patients with previously untreated RCC. Dr Choueiri goes on to discuss where these data fit into the complex treatment paradigm of RCC.
Promising avelumab plus axitinib data in renal cell carcinoma
23 Nov 2018
avelumab
axitinib
Bavencio
checkpoint inhibitors
combination therapy
first-line treatment
immunotherapy
Inlyta
renal cell carcinoma
sunitinib
Sutent
targeted therapy
TKIs
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab pembrolizumab COVID-19 cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers papillary RCC targeted therapy everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec